NanoViricides (NYSE-A:NNVC), a leader in broad-spectrum antiviral nanomedicines, is advancing its development program for NV-387.
This single drug has shown activity against various respiratory viral infections in animal models.
NV-387 has shown superior activity against RSV, a cold-like virus, influenza, coronaviruses, and orthopoxviruses in animal models, protecting lungs from damage and completely curing RSV infections in animals.
The drug's design, mimicking host cells, makes it difficult for viruses to develop resistance.
In this context, the company noted that a fifth human case of H5Nx Bird Flu was reported in Colorado, involving a person who contracted the virus from infected dairy cattle.
The patient, treated with Tamiflu, has recovered, and scientists state that the risk of human-to-human transmission remains low. However, H5N1 bird flu is widespread among wild birds and has infected many mammals.
MPox infections are also rising in the Western world, with an increase in cases in the USA. Additionally, a summer surge of COVID-19 is occurring due to new FLiRT variants.
The traditional approach of developing separate drugs for each virus is costly and impractical. NV-387 challenges this model by offering a single drug effective against multiple viruses, simplifying pandemic preparedness and reducing development costs.
NV-387 has completed phase I clinical trials with no adverse events reported, indicating excellent safety. The clinical trial site is undergoing audits for regulatory compliance, with statistical data analysis expected to begin soon.
NanoViricides (NYSE-A:NNVC) is planning phase II clinical studies for NV-387 as a treatment for RSV, Influenza, and COVID-19. The company aims to pursue the fastest regulatory approval paths in various countries, including the USA.